Paper37745244
Blocking cholesterol formation and turnover improves cellular and mitochondria function in murine heart microvascular endothelial cells and cardiomyocytes.
Braczko A and 8 others. Front Physiol, 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Blocking cholesterol formation and turnover improves cellular and mitochondria function in murine heart microvascular endothelial cells and cardiomyocytes. Papers, record 37745244. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37745244
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Blocking cholesterol formation and turnover improves cellular and mitochondria function in murine heart microvascular endothelial cells and cardiomyocytes.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31766595 | Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. | J Clin Med | 2019 | https://conductscience.org/library/papers/31766595 | PubMed |
| 2 | 24103783 | Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding. | J Lipid Res | 2013 | https://conductscience.org/library/papers/24103783 | PubMed |
| 3 | 36045572 | Statin-induced increase in actin polymerization modulates GPCR dynamics and compartmentalization. | Biophys J | 2023 | https://conductscience.org/library/papers/36045572 | PubMed |
| 4 | 33511728 | Effects of statins on mitochondrial pathways. | J Cachexia Sarcopenia Muscle | 2021 | https://conductscience.org/library/papers/33511728 | PubMed |
| 5 | 34676866 | A Modern Approach to Dyslipidemia. | Endocr Rev | 2022 | https://conductscience.org/library/papers/34676866 | PubMed |
| 6 | 30374710 | Uncoupling protein 3 deficiency impairs myocardial fatty acid oxidation and contractile recovery following ischemia/reperfusion. | Basic Res Cardiol | 2018 | https://conductscience.org/library/papers/30374710 | PubMed |
| 7 | 25911648 | Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. | Eur Heart J | 2015 | https://conductscience.org/library/papers/25911648 | PubMed |
| 8 | 35884844 | CoCl2-Mimicked Endothelial Cell Hypoxia Induces Nucleotide Depletion and Functional Impairment That Is Reversed by Nucleotide Precursors. | Biomedicines | 2022 | https://conductscience.org/library/papers/35884844 | PubMed |
| 9 | 32674634 | Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia. | J Am Heart Assoc | 2020 | https://conductscience.org/library/papers/32674634 | PubMed |
| 10 | 30761308 | Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. | Front Cardiovasc Med | 2018 | https://conductscience.org/library/papers/30761308 | PubMed |
| 11 | 19278604 | The role of statins in the treatment of the metabolic syndrome. | Curr Hypertens Rep | 2009 | https://conductscience.org/library/papers/19278604 | PubMed |
| 12 | 20558442 | Endothelial mitochondria and heart disease. | Cardiovasc Res | 2010 | https://conductscience.org/library/papers/20558442 | PubMed |
| 13 | 34112278 | RNAi of vacuolar-type H+-ATPase genes causes growth delay and molting defect in Henosepilachna vigintioctopunctata. | Bull Entomol Res | 2021 | https://conductscience.org/library/papers/34112278 | PubMed |
| 14 | 30207556 | PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. | Rev Cardiovasc Med | 2018 | https://conductscience.org/library/papers/30207556 | PubMed |
| 15 | 35048716 | Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. | J Am Heart Assoc | 2022 | https://conductscience.org/library/papers/35048716 | PubMed |
| 16 | 23580773 | Mitochondria and endothelial function. | Circ Res | 2013 | https://conductscience.org/library/papers/23580773 | PubMed |
| 17 | 32586319 | Integrative analyses of gene expression profile reveal potential crucial roles of mitotic cell cycle and microtubule cytoskeleton in pulmonary artery hypertension. | BMC Med Genomics | 2020 | https://conductscience.org/library/papers/32586319 | PubMed |
| 18 | 32329440 | PCSK9 promotes the secretion of pro-inflammatory cytokines by macrophages to aggravate H/R-induced cardiomyocyte injury via activating NF-κB signalling. | Gen Physiol Biophys | 2020 | https://conductscience.org/library/papers/32329440 | PubMed |
| 19 | 32899944 | Coronary Microvascular Dysfunction. | J Clin Med | 2020 | https://conductscience.org/library/papers/32899944 | PubMed |
| 20 | 29718253 | Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. | Eur Heart J | 2018 | https://conductscience.org/library/papers/29718253 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42181884 | Evolocumab early reduces IL-1β/IL-17A and improves left ventricular function in STEMI: an observational study in the real world. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42181884 | PubMed |
| 40648946 | Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors. | J Clin Med | 2025 | https://conductscience.org/library/papers/40648946 | PubMed |
| 40076547 | PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40076547 | PubMed |
| 39816559 | Mitochondrial cholesterol metabolism related gene model predicts prognosis and treatment response in hepatocellular carcinoma. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/39816559 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GSK3B | 2932 | PubTator's text mining | https://conductscience.org/library/genes/2932 | NCBI Gene |
| HIF1A | 3091 | PubTator's text mining | https://conductscience.org/library/genes/3091 | NCBI Gene |
| NOS3 | 4846 | PubTator's text mining | https://conductscience.org/library/genes/4846 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37745244
GET https://conductscience.org/api/papers/v1/37745244/references?page=2